A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects

NCT ID: NCT02003547

Last Updated: 2014-05-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-09-30
• Study Completion Date: 2013-12-31

Brief Summary

A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects

Detailed Description

Each subject will receive the following treatments:

• Period 1: Formulation A (n = 14) or placebo (n = 7) twice daily for 7 days
• Period 2: Formulation B (n = 14) or placebo (n = 7) twice daily for 7 days
• Period 3: Formulation C (n = 14) or placebo (n = 7) twice daily for 7 days

There will be a minimum washout of 7 days between each treatment period (last dose of previous period to first dose of subsequent period

Conditions

Glaucoma; Ocular Hypertension; Eye Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AMA0076 Formulation A

Topical Ocular Drop BID X 1 wk

Group Type: EXPERIMENTAL

AMA0076

Intervention Type: DRUG

AMA0076 Formulation B

Topical Ocular Drop BID X 1wk

Group Type: EXPERIMENTAL

AMA0076

Intervention Type: DRUG

AMA0076 Formulation C

Topical Ocular Drop BID X 1 wk

Group Type: EXPERIMENTAL

AMA0076

Intervention Type: DRUG

Placebo

Topical Ocular Drop BID X 1 wk

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

AMA0076

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy males and non-pregnant, non-lactating females, aged 35 to 65 years.
• Body mass index of ≤35kg/m2.
• IOP between 15 and 24 mmHg (inclusive) in both eyes at Screening Visits 1 and 2.

Exclusion Criteria

• Women of child-bearing potential who have a positive pregnancy test.
• Any subject deemed by the investigator to have uncontrolled systemic hypertension
• Use of systemic, inhaled or ocular corticosteroid treatment within 90 days of screening or likely to require their use during the study period.
• Any screening laboratory abnormality that, in either the investigator's or the medical monitor's judgment, is considered to be clinically significant or a safety risk.
• History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject's ability to participate in the study, or interfere with interpretation of the subject's study results.
• Participation in any other clinical study within 1 month of screening or during the study.
• Receipt of another investigational drug within 90 days of dosing in this study
• Diagnosis of any form of glaucoma.
• IOP >24 mmHg in either eye at any screening visit.
• Use of any ocular drops (including lubricating drops/artificial tears) during screening period or need for ocular drops during duration of study participation.
• In the opinion of the investigator, clinically significant eye trauma within 6 months of screening.
• Any intraocular ophthalmic procedure within 6 months of screening.
• Any ocular inflammation within 90 days of screening or a history of recurrent uveitis in either eye.
• Subjects with any known ocular disease and who are under care of a hospital ophthalmologist.
• Any condition preventing valid applanation tonometry measurement.
• Unable to discontinue contact lens wear during the study
• Visual acuity (VA) worse than 20/80 in either eye
• Subjects who are study site employees, or immediate family members of a study site or sponsor employee.
• History of any drug or alcohol abuse in the past 2 years.
• Regular alcohol consumption.
• Positive drugs of abuse test result.
• Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
• Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
• Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Amakem, NV

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Stuart Mair, MD

Role: PRINCIPAL_INVESTIGATOR

Quotient Clinical

Locations

Ruddington, Nottingham, United Kingdom

Countries

United Kingdom

Other Identifiers

2013-002334-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AMA0076-M-101

Identifier Type: -

Identifier Source: org_study_id